drugset / Trial / NCT03929120
Allogeneic Bone Marrow Mesenchymal Stem Cells for Patients With Interstitial Lung Disease (ILD) & Connective Tissue Disorders (CTD)
NaSingle-groupOpen-labelTreatment
Summary
Researchers are trying to find out more about the safety of a new treatment, Allogeneic (coming from a healthy donor) Bone Marrow Derived Mesenchymal Stem Cells (BMD-MSCs) which is still experimental, for Interstitial Lung Disease (ILD) associated with Connective Tissue Disorder (CTD).
Timeline
- Start
- 2019-11-05
- Primary completion
- 2021-07-27
- Completion
- 2022-02-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Mesenchymal stem cell | Cell therapy | 500000 cells/kg | Intravenous |
| Subject | Mesenchymal stem cell | Cell therapy | 1e+06 cells/kg | Intravenous |